Brought to you by 
Suzhou Connect gets license to two of Arena's drug candidates
16 Aug 2012
Executive Summary
Suzhou Connect Biopharmaceuticals Ltd. (newly formed Chinese company focused on GPCRs for autoimmune diseases, allergies, and cancer), through its US division Connect Biopharm LLC, has received exclusive global rights to two of Arena Pharmaceuticals Inc.’s small-molecule drug candidates for allergic rhinitis and atopic dermatitis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Suzhou Connect gets license to two of Arena's drug candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice